case_images: PMC10359678_01
case_images: Timeline for the patient.
case_images: cro-2023-0016-0001-530547_F01.jpg
case_images: PMC10359678_01_cro-2023-0016-0001-530547_F01.jpg
case_images: F1
case_images: Thereafter, the patient was treated with an LH-RH agonist and enzalutamide; however, progression occurred on both (Fig. 1).
case_images: The dynamics of serum concentrations of cabazitaxel (CBZ) and clarithromycin (CAM). The horizontal axis shows the day the patient was first admitted was set as day 0. The vertical axis shows CBZ or CAM concentrations. White dots ( ) and black dots ( ) are shown for CBZ and CAM, respectively. LLD, limit of lower detection.
case_images: cro-2023-0016-0001-530547_F02.jpg
case_images: PMC10359678_01_cro-2023-0016-0001-530547_F02.jpg
case_images: F2
case_images: Liquid chromatography with tandem mass spectrometry revealed cabazitaxel and clarithromycin concentrations of 1.0 ng/mL and 69.7 ng/mL, respectively, on day 0 and 1.2 ng/mL and below the limit of lower detection (<20 ng/mL) on day 28 (Fig. 2).